Presentations

Proteomics for Systems Toxicology

Titz, B.; Nury, C.; Schneider, T.; Kogel, U.; Iskandar, A. R.; Elamin, A.; Sewer, A.; Martin, F.; Ivanov, N. V.; Vanscheeuwijck, P.; Peitsch, M. C.; Hoeng, J.
Conference date
Jul 6, 2017
Conference name

5th International Conference on Analytical Proteomics (ICAP) 2017
Link to more information
Topic
Summary

No abstract available.

Related Publications

Effects of a Modified Exposure Claim for an e-Cigarette on Claim Comprehension, Behavioral Intentions, and Risk Perceptions Among US Adult Tobacco Users and Nonusers: Randomized Experimental Study

electronic cigarettes;Public health;Risk perceptions;switching

Toxicological risk assessment of VEEV NOW ULTRA e-vapor products shows reduced toxicity compared to cigarette smoke

E-Vapor Products;Toxicological assessment;E-liquid ingredients

Toxicological risk assessment framework for e-vapor products: From product ideation to product commercialization

E-Vapor Products;Toxicological assessment;E-liquid ingredients

Randomized studies assessing the effect of flavor on pharmacokinetic and subjective parameters for dry and moist nicotine pouches

Nicotine pharmacokinetics;Clinical

Scientific Update June 2025 Issue 21

Harm reduction;Nicotine;Scientific Update;Smoke-free products;Research;Perception and Behavior;E-Vapor Products

Scientific Update October 2025 Issue 22

Smoke-free products;Post-Market Studies and Surveillance Study

PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
​
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.